期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

左卡尼汀与促红细胞生成素联用治疗维持性血透肾性贫血临床探讨 被引量：6

暂未订购
导出
摘要 目的:探讨维持性血透肾性贫血采用左卡尼汀联合促红细胞生成素治疗的临床效果。方法:本次研究选择我院2009年1月～2012年1月收治的行维持性血透慢性贫血患者80例,随机分为两组,对照组40例采用促红细胞生成素治疗,观察组40例在此基础上联用左卡尼汀治疗,就两组临床资料进行回顾性分析。结果:与治疗前比较,治疗后HCT、Hb均有所增高(P<0.05),观察组增高幅度显著高于对照组(P<0.05)。与治疗前比较,两组血白蛋白治疗后均显著升高(P<0.05)。但两组间白蛋白升高水平、血磷、血脂浓度比较无明显差异(P>0.05)。对照组明显多于观察组促红细胞生成素用药剂量(P<0.05)。观察组血压升高1例,明显少于对照组6例(P<0.05),两组胃肠道反应比较差异无统计学意义(P>0.05)。结论:左卡尼汀与促红细胞生成素联用治疗维持性血透肾性贫血临床效果满意,明显改善了患者生存质量。
作者 谢军
机构地区 贵州省毕节市人民医院
出处 《北方药学》 2012年第7期108-108,共1页 Journal of North Pharmacy
关键词 左卡尼汀 促红细胞生成素 维持性血透 肾性贫血
分类号 R459.5 [医药卫生—治疗学]
  • 相关文献

参考文献2

二级参考文献17

  • 1Wanner C,Wanner SF,Rosslee C,et al.Carnitine metabolism in patients with chronic renal failure;Effect of L-carmitine suoole mentasion[J].Kidney Int,1987,32(suppl 22):132.
  • 2Josef K,Gert M,Elisabeth L,et al.Anemia and carnitine supple mentation in hemodialyzed patients[J].Kindey Int,1999,55(suppl 69):93-106.
  • 3Labonia M D.L-carnitine effect on anemia in hemosialyzed patients treaded with erythropoitn[J].Am J Kidney Dis,1995,26(5):757.
  • 4Bellinghieri G,Santoro D,Calvani M,et al.Carnitine and hemodialysis[J].Am J Kidney Dis,2003,41(3 suppl 1):S116.
  • 5Borum PR,Plasma carnitine compartment and red blood cell curnitine compartment of healthy adults[J]. Am J Clin Nutr, 1987,46:437-441.
  • 6Goa KL, Brogckn RN. L - carnitine: a preliminary review of its pharmaco kinetics and its therapeutic use in lischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs, 1987,34:21-24.
  • 7Arduine A,Holme S,Sweeney JD,et al. Addition of L- carnitine to additire solutiorr - suspended red cell stored at 40 c reduces in vitro hemolysis and improves in vivoviability [ J ]. Transfusion, 1997,37: 166-174.
  • 8Donatelli,M,Terrizzi C,Zumro G,Russo V,Bucdo M,Scarpinaro A, Effects o L - earnitine on chronic anemia and adenosine triphosphate concentration in hemodialyzed patients. Curv Ther Res, 1987,41 : 620-624.
  • 9Agroyannis B,Parakeropoulos A,Fourtounas C, et al .Effect of L - carnitine on the calcium contant of erythrocytes of uremic patients on hemodialysis. Dial Transplant 2002,31 : 106-128.
  • 10Kletzmayr J,Mayer G,legenstein E,et al. Ancmia and carmitine supplementation in hemodialyzed patients [ J ]. Kidney Int, 1999, 55 (69):93-106.

共引文献20

同被引文献48

  • 1毕光宇,魏丛军.左卡尼汀提高维持性血液透析患者促红细胞生成素反应性疗效观察[J].南京医科大学学报（自然科学版）,2007,27(4):339-340. 被引量：3
  • 2邓新.左卡尼汀联合EPO治疗维持性血透患者肾性贫血的临床观察[J].海南医学,2007,18(10):89-90. 被引量：1
  • 3Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res, 2007,30 (1) :15 -30.
  • 4Pinto JP, Dias V, Zoller H, et al. Hepcidin MessengerRNA Ex- pression in Human Lymphocytes. Immunology, 2010, 130 ( 2 ) : 217 - 230.
  • 5Guarnieri G, Biolo G, Vinci P, et al. Advances in camitine inchronic Uremia. J Ren Nutr,2007,17 ( 1 ) :23 - 29.
  • 6Martin GB, Mansion F, Servais AC, et al. CE MS methos devel- opment for peptides analysis, dspecially hepcidin, an iron me- tabolism maker. Electroresis, 2009,30 (15) 2624 - 2631.
  • 7Bslogh A, Bosze S, Horvati K, et al. Role of iron Metabolism regulator hepcidin in perinatal iron homeostasis. Orv Hetil, 2010,151(3) :83 -91.
  • 8Ganz T. Hepcidin : a regulator of intestinal iron absorption and i- ron recycling by macrophages. Best Pract Clin Haematol,2005, 18(2) :171 - 182.
  • 9Nicolasg, Bennounm, Devaux I, eta. 1 Lack ofhepcidin gene ex- pression and severe tissue iron overload in upstream stmi ulatory factor 2 (USF2)knockoutmice. Proc Natl Acad Sci USA ,2001, 98 ( 15 ) : 8780 - 8785.
  • 10Fleming RE, Slyw S. Hepcidin:a putative iron regulatory hor- mone relevant to hereditary hemochromatosis and tne anemia of chronic disease . ProcNatlAcad Sci, 2001,98 ( 15 ) : 8160 - 8162.

二级引证文献64

北方药学
2012年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部